01714nam a2200385 i 4500001001300000003000300013005001700016006001900033007001500052008004100067040003400108042000800142043001200150050002000162074002000182086002300202088010200225110009400327245020500421264006000626300003800686336002600724337002600750338003600776500010800812500002600920500002500946504004100971588012001012610003601132650003901168650005001207655003301257856003801290ocn984515142BD20180507195054.0m     o  d f      cr bn||||a||||170427s2017    dcu     ob   f000 0 eng c  aPUCPRbengerdaepncGPOdMvI  apcc  an-us---14aKF27b.O94 2016  a1016-C (online)0 aY 4.G 74/7:114-124  aSerial no. 114-124 (United States. Congress. House. Committee on Oversight and Government Reform)1 aUnited States.bCongress.bHouse.bCommittee on Oversight and Government Reform,eauthor.10aReviewing the rising price of EpiPens :bhearing before the Committee on Oversight and Government Reform, House of Representatives, One Hundred Fourteenth Congress, second session, September 21, 2016. 1aWashington :bU.S. Government Publishing Office,c2017.  a1 online resource (iii, 95 pages)  atextbtxt2rdacontent  acomputerbc2rdamedia  aonline resourcebcr2rdacarrier  aPaper version available for sale by the Superintendent of Documents, U.S. Government Publishing Office.  a"Serial no. 114-124."  aCRDP Program record.  aIncludes bibliographical references.  aDescription based on online resource, PDF version; title from title page (FDsys web site, viewed on Apr. 26, 2017).20aMylan, Inc.xCorrupt practices. 0aAdrenalinexPriceszUnited States. 0aDrug delivery devicesxPriceszUnited States. 7aLegislative hearings.2lcgft40uhttp://purl.fdlp.gov/GPO/gpo80186